Viatris Upgraded to Buy, Price Target Rises to $18 and Inpefa Debuts in UAE
UBS upgraded Viatris to Buy from Neutral and lifted its price target to $18 from $11, citing efficient capital allocation, rising profits and a strengthening product pipeline. Viatris also launched its dual SGLT1/2 inhibitor Inpefa in the UAE as the first market outside the U.S., with additional global rollouts planned.
1. UBS Upgrade and Price Target Revision
UBS upgraded Viatris from Neutral to Buy and raised its price target to $18 from $11, reflecting increased confidence in the company’s financial trajectory and valuation potential.
2. Upgrade Drivers
The upgrade was driven by efficient capital allocation, ongoing cost-cutting initiatives and a robust product pipeline expected to boost profitability and shareholder returns over the coming quarters.
3. Inpefa Launch in UAE
Viatris launched Inpefa, a first-in-class dual SGLT1/2 inhibitor for heart failure patients, in the UAE as its first market outside the U.S., targeting reductions in cardiovascular death and hospitalizations.
4. Global Rollout and Upcoming Events
Regulatory submissions in Canada, Australia and Mexico are underway, with further launches planned prior to the March 19 investor event and ahead of the fourth-quarter and full-year 2025 results on February 26.